Sarah L Reeves1,2, Alison C Tribble3,2, Brian Madden3,2, Gary L Freed3,2, Kevin J Dombkowski3,2. 1. Department of Pediatrics and Communicable Diseases and sleasure@med.umich.edu. 2. Child Health Evaluation and Research (CHEAR) Center, University of Michigan, Ann Arbor, Michigan. 3. Department of Pediatrics and Communicable Diseases and.
Abstract
BACKGROUND: Children with sickle cell anemia (SCA) are at increased risk for invasive pneumococcal disease; antibiotic prophylaxis significantly reduces this risk. We calculated the proportion of children with SCA who received ≥300 days of antibiotic prophylaxis and identified predictors of such receipt. METHODS: Children aged 3 months to 5 years with SCA were identified by the presence of 3 or more Medicaid claims with a diagnosis of SCA within a calendar year (2005-2012) in Florida, Illinois, Louisiana, Michigan, South Carolina, and Texas. Receipt of antibiotics was identified through claims for filled prescriptions. The outcome, receipt of ≥300 days of antibiotics, was assessed annually by using varying classifications of antibiotics. By using logistic regression with generalized estimating equations, we estimated the odds of receiving ≥300 days of antibiotics, with potential predictors of age, sex, year, state, and health services use. RESULTS: A total of 2821 children contributed 5014 person-years. Overall, only 18% of children received ≥300 days of antibiotics. Each additional sickle cell disease-related outpatient visit (odds ratio = 1.01, 95% confidence interval: 1.01-1.02) and well-child visit (odds ratio = 1.08, 95% confidence interval: 1.02-1.13) was associated with incrementally increased odds of receiving ≥300 days of antibiotics. CONCLUSIONS: Despite national recommendations and proven lifesaving benefit, antibiotic prophylaxis rates are low among children with SCA. Numerous health care encounters may offer an opportunity for intervention; in addition, such interventions likely need to include social factors that may affect the ability for a child to receive and adhere to antibiotic prophylaxis.
BACKGROUND:Children with sickle cell anemia (SCA) are at increased risk for invasive pneumococcal disease; antibiotic prophylaxis significantly reduces this risk. We calculated the proportion of children with SCA who received ≥300 days of antibiotic prophylaxis and identified predictors of such receipt. METHODS:Children aged 3 months to 5 years with SCA were identified by the presence of 3 or more Medicaid claims with a diagnosis of SCA within a calendar year (2005-2012) in Florida, Illinois, Louisiana, Michigan, South Carolina, and Texas. Receipt of antibiotics was identified through claims for filled prescriptions. The outcome, receipt of ≥300 days of antibiotics, was assessed annually by using varying classifications of antibiotics. By using logistic regression with generalized estimating equations, we estimated the odds of receiving ≥300 days of antibiotics, with potential predictors of age, sex, year, state, and health services use. RESULTS: A total of 2821 children contributed 5014 person-years. Overall, only 18% of children received ≥300 days of antibiotics. Each additional sickle cell disease-related outpatient visit (odds ratio = 1.01, 95% confidence interval: 1.01-1.02) and well-child visit (odds ratio = 1.08, 95% confidence interval: 1.02-1.13) was associated with incrementally increased odds of receiving ≥300 days of antibiotics. CONCLUSIONS: Despite national recommendations and proven lifesaving benefit, antibiotic prophylaxis rates are low among children with SCA. Numerous health care encounters may offer an opportunity for intervention; in addition, such interventions likely need to include social factors that may affect the ability for a child to receive and adhere to antibiotic prophylaxis.
Authors: Sarah L Reeves; Thomas M Braun; Kevin J Dombkowski; Heather J Fullerton; Matthew L Boulton; Lynda D Lisabeth Journal: J Pediatr Hematol Oncol Date: 2015-05 Impact factor: 1.289
Authors: David G Anders; Fei Tang; Tatania Ledneva; Michele Caggana; Nancy S Green; Ying Wang; Lawrence S Sturman Journal: Am J Prev Med Date: 2016-07 Impact factor: 5.043
Authors: M H Gaston; J I Verter; G Woods; C Pegelow; J Kelleher; G Presbury; H Zarkowsky; E Vichinsky; R Iyer; J S Lobel Journal: N Engl J Med Date: 1986-06-19 Impact factor: 91.245
Authors: Natasha B Halasa; Sadhna M Shankar; Thomas R Talbot; Patrick G Arbogast; Ed F Mitchel; Winfred C Wang; William Schaffner; Allen S Craig; Marie R Griffin Journal: Clin Infect Dis Date: 2007-04-18 Impact factor: 9.079
Authors: Jennifer Michlitsch; Mahin Azimi; Carolyn Hoppe; Mark C Walters; Bertram Lubin; Fred Lorey; Elliott Vichinsky Journal: Pediatr Blood Cancer Date: 2009-04 Impact factor: 3.167
Authors: Sarah L Reeves; Hannah K Jary; Jennifer P Gondhi; Jean L Raphael; Lynda D Lisabeth; Kevin J Dombkowski Journal: Clin Pediatr (Phila) Date: 2019-05-21 Impact factor: 1.168
Authors: Sarah L Reeves; Gary L Freed; Brian Madden; Meng Wu; Lauren Miller; Lindsay Cogan; David Anders; Susan E Creary; Julie McCormick; Kevin J Dombkowski Journal: Pediatr Blood Cancer Date: 2021-12-02 Impact factor: 3.838
Authors: Christopher McKinney; Amy Caruso-Brown; Kathleen Montgomery; Anne Gillespie; Rebecca Coughlin; Dawn Law; Anna Brouwer; Lauren Tytler; Joanne Hilden; Rachelle Nuss Journal: Pediatr Qual Saf Date: 2020-01-10